Diabetes: Jupiter Trial

Do not be fooled by the Jupiter trial with respect to the efficacy of statins. The large percentage benefits are Relative Risk and mean very little. Statins have been sold based on relative risk number rather tha absolute risk from the beginning, In the case of the Jupiter Trial the Absolute Risk reduction is on the order of 1.2%, not the huge phony numbers like 50 plus something percent. These are valid calculations, but as humans we are susceptible to the "large number" sales technique. In truth, the absolute risk improvement demonstrated in the Jupiter Trial is clinically insignifiacant, as it is clinically insignificant for all of the statin trials, yet we all pile on the bandwagon and urge the use of drugs known to have nad side effects. The stains look much less appealing when one weighs the risk to benefit ratios in light of absolute risk rather than the cooked books realtive risk.